Research Paper Volume 13, Issue 23 pp 25089—25105
The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism
Figure 2. Puerarin inhibits PCC invasion and migration by antagonizing the Slug-E-cadherin axis. (A, B) The effect of puerarin on the migrated rate of PDACs was determined by the wound healing assay. (C, D) The effects of puerarin on the invading number of PDACs were analyzed by the transwell chamber assay. (E) Western blot analysis showing the expression of E-cadherin and α-SMA in puerarin-treated PDACs. (F) Immunocytochemical staining of E-cadherin and α-SMA in puerarin-treated PDACs. Bar = 25 μm. The data are presented as the mean ± standard deviation and were analyzed by one-way ANOVA with Bonferroni’s post-hoc test. *p < 0.05, **p < 0.01, and ***p < 0.001.